SCHEMBL2905574

SCHEMBL2905574

COc1ccc(I)nc1OC1CCCC1

nearest known ligand 0.42

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 10/20 0.42
PDGFRB P09619 3/20 0.42
PDGFRA P16234 3/20 0.42
PDE4B Q07343 9/20 0.40
PDE4C Q08493 8/20 0.40
PDE4D Q08499 8/20 0.40
S1PR1 P21453 1/20 0.39
S1PR3 Q99500 1/20 0.39
FFAR4 Q5NUL3 1/20 0.38
POLB P06746 1/20 0.38
LRRK2 Q5S007 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2910247 0.97 FFAR4 (0.40) PDE4APDGFRBPDGFRAPDE4BPDE4C
SCHEMBL30350700 0.97 FFAR4 (0.40) PDE4APDGFRBPDGFRAPDE4BPDE4C
SCHEMBL2414839 0.87 PDE4A (0.42) PDE4APDGFRBPDGFRAPDE4BPDE4C
SCHEMBL6607678 0.82 FFAR4 (0.43) PDE4APDGFRBPDGFRAPDE4BPDE4C
SCHEMBL2905403 0.81 PDE4D (0.44) PDE4APDE4BPDE4CPDE4DLRRK2
SCHEMBL2903176 0.81 PDE4D (0.44) PDE4APDE4BPDE4CPDE4DLRRK2
SCHEMBL26151328 0.77 MCHR1 (0.46) PDE4APDGFRBPDGFRAPDE4BPDE4C
SCHEMBL2905855 0.77 PDE4D (0.39) PDE4APDE4BPDE4CPDE4DLRRK2
SCHEMBL441334 0.77 KMT2A (0.39)
SCHEMBL70397 0.76 KDM4E (0.53) PDE4APDE4BPDE4CPDE4DFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
US-20090118270-A1 PHOSPHODIESTERASE 4 INHIBITORS TALAMAS FRANCISCO XAVIER 2009-05-07 US disclosed
EP-1888528-A2 PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceuticals Corporation (US) 2008-02-20 EP disclosed
US-20070049611-A1 Phosphodiesterase 4 inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US disclosed
CN-1922144-A Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs MEMORY PHARM CORP (US) 2007-02-28 CN disclosed
WO-2006135828-A2 TRISUBSTITUTED AMINES AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2006-12-21 WO disclosed
EP-1692109-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS Memory Pharmaceuticals Corporation (US) 2006-08-23 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed
WO-2005061458-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARMACEUTICALS CORPORATION (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049611-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE3B, PDE4B PDE4A 1/4885PDGFRB 543/4885PDGFRA 885/4885
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B PDE4A 1/4885PDGFRB 556/4885PDGFRA 778/4885
US-20090118270-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE3B, PDE4B PDE4A 1/4885PDGFRB 543/4885PDGFRA 885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.